Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

Glioblastoma multiforme (GBM) is the most common and aggressive primary central nervous
system malignancy with a median survival of 15 months. The average incidence rate of …

… By contrast, EANO guidelines consider systemic pharmacotherapy to be experimental,
with level C evidence for grade III or progressive grade II meningioma and do not recommend …

The factors driving therapy resistance in diffuse glioma remain poorly understood. To
identify treatment-associated cellular and genetic changes, we analyzed RNA and/or DNA …

… for 1 hour with 5% nonfat dry milk in 20 mmol/L potassium phosphate, and 150 mmol/L
potassium chloride, pH 7.4 containing 0.3% (w/v) Tween 20 and then probed overnight at 4C with …

In many aggressive cancers, such as glioblastoma multiforme, progression is enabled by
local immunosuppression driven by the accumulation of regulatory T cells (Treg) and myeloid-…

… c, Univariate survival analysis revealed that only response to anti-PD-1 therapy is significantly
correlated with overall survival of the patients (n = 25); P value, two-sided log-rank test. d, …

Glioblastoma (GBM) is one of the most difficult cancers to effectively treat, in part because of
the lack of precision therapies and limited therapeutic access to intracranial tumor sites due …

… heated at 37C for 30 minutes to ensure incorporation of the cores into the block. The block
was then cut into 5-μm-thick sections, and unstained slides were stored at 4C until needed. …

Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive pediatric brainstem tumor
characterized by rapid and uniform patient demise 1 . A heterozygous point mutation of histone …